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measured immediately. This is not the case for
radiotherapy where debilitating of even lethal
side effects may show up as late as 18 years
after treatmenł. To determine the outcome or
therapeutic ratio of radiotherapy, it is therefore
necessary to Iink tumour control closely to the
actuarial long-term disease free survival of the
patienł.
The therapeutic window for radiotherapy is
narrow. In walking the tightrope between cure
and complications, radiotherapy can put the
odds at its side. As a precautionary measure,
strict quality assurance measures including the
monitoring of side effects need to be put in
place. Recent studies have demonstrated that
every gain in the accuracy of the beam output
and treatment delivery is translated into
important gains in the uncomplicated cure
probability, thus sparing the lives of thousands
of patients every year. QA will become all the
more mandatory now that new technological
developments allow much more precision in the
delivery of the intended dose to the intended
target volume, thus making an escalation of the
dose and hence the improvement of the cancer
cure rata possible.
Europe has only half the number of treatment
units of America and Japan. However, it has
also its own strengths. These are exactly in the
field of quality assurance and education.
ESTRO has become a world leader in the
provision of teaching in the field of radiotherapy.
The ESTRO teaching programme commands
the admiration and even the envy of the
International radiation oncology community. We
need to capitalise on this achievement and keep
it at the cutting edge of scientific and
technological progress to offset, through the
development of the human potential and optima)
use of capital-intensive infrastructural resources,
at least partially the shortage in capital
investment and the past shortfall in spending for
research.
For this reason ESTRO is embarking on an
ambitious new project called ESQUIRE
(Education, Science and Quality Assurance In
Radiotherapy in Europe) which it hopes to
realise with the support of EU funding. The aim
of this project is to increase the confidence level
of clinicians for embracing optimised RT
treatment regimes by making sure they can be
introduced without an increase in severe side
effects. Actions proposed for this purpose:
monitoring the accuracy of the dose (Talk
1:E-UAL) and the side effects (Task 2: REACT),
by stepping up education for the implementation
of new technology (Task 3: EDRO,) by
developing quality assurance procedures for
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optimised RT (Task 5: QUASIMODO) and
brachytherapy (Task 6: BRAPHY-S), and
establishing a procedure-based surveillance of
quality in treatment and research (Task
4:EPOQART).
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The International Union for Physical and
Engineering Sciences in Medicine
(IUPESM)comprises a global network of 40,000
graduate physical scientists and engineers in
about 100 countries. IUPESM has two
constituent organisations, the International
Organisation for Medical Physics (IOMP) and
the International Federation for Medical and
Biological Engineering (EFMBE).
IUPESM has sponsored triennial World
Congresses in many countreis since 1967. The
Millennium Congress was held in Chicago, USA,
with 6500 participants from 70 countries with
4000 aral presentations and posters.
Regional scientific meetings, educational
courses and scientific conferences are also.
IUPESM, IOMP, IFMBE have interrelated
Working Groups such as the Science
Committee, Publications Committee and
Education and Training Committee
Many journals belong to or are associated with
IUPESM through our international and national
member societies, as listed on the IUPESM
Global Knowledge Network for Medicine,
Physics and Bioengineering (http://www.wc
2000.org/).The main area of IUPESM and IOMP
activities are:
(1) Education, Training and Continued
Professional Development for the 21 st
Century with particular reference to
Developing and Emerging Countries.
(2) Global Biomedical Information Networking
for Developing and Emerging Countries.
(3) Evidence Based Health Technology.This
programme is aimed at international
assessment of the health benefits and
cost-etfectiveness of existing and new
technologies in Health Care.
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(4) Medical Equipment Evaluation. This
programme's aims are to establish and
promote international protocols and
standards for Performance Testing,
Quality Assurance, Safety and
Environmental aspects.
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Intractable bone pain secondary to bone
metastasis from prostate or breast cancer, or
other malignancies is a major problem in the
management of the oncological patient.
Treatment often includes the use of analgesic
drug therapy; however, radiation therapy,
hormonal therapy, chemotherapy, and surgery
mayaiso be needed. Advances in systemic
radionuciide therapy have increased the number
of treatment options available for patients with
painful osseous metastases. This treatment
modality offers three major advantages L) by
addressing all sites of involvement; and ii) by
limiting irradiation of normai tissues due to
selective absorption into bone which results in
an improved therapeutic ratio. Patients with a
positive bone scan are eligible for treatment,
and indications and contraindications for use are
well defined. Large, prospectively randomized
c1inical triais have established the efficacy of
samarium-153 EDTMP and strontium-89 CI as a
first-line therapy. When these agents are used,
pain relief often occurs rapidly and lasts several
weeks to months with responses seen in 60-
80% of patients, depending on the extent and
stage of the disease. With the introduction of
modern bone-seeking radiopharmaceuticals as
Sm-153 EDTMP toxicity is rare and restricted to
reversible myelosuppression. In summary,
evidenced based Iiterature suggests that these
radiopharmaceuticals can significantly reduce
pain and analgesic requirements, improve
quality of life, reduce lifetime radiotherapy
requirements and management costs, and may
even slow the progression of painful metastatic
lesions. Retreatment is safe and effective.
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The aims of radioiodine C31 I) therapy for
patients with differentiated thyroid carcinomas:
D Destruction of thyroid tissue remaining after
thyroidectomy
D Destruction of microcarcinoma focus in site
of thyroid
D Destruction of metastases in Iymph nodes
D Destruction of distant metastases
Therapeutic indications for radioiodine
C31 I) treatment in differentiated thyroid
carcinomas
D Complementary treatment
This treatment is recommended in all patients
with follicular or papillary carcinomas in stage
pT1b-4 NO' 1 Mo after total thyroidectomy. In some
cases it could be as the complementary
treatment after incomplete thyroidectomy.
The recommended radioiodine activity for the
complementary therapy is from 1.75 to 3.5 GBq
(60 - 150 mCi)
D Radical treatment
This kind of treatment is recommended for
patients with differentiated thyroid carcinomas
and remote metastases. If the lesions
concentrate 131 I in quantities sufficient for
radical treatment - the patient can be treated
with the isotope.
D Palliative treatment
Palliative treatment is recommended for patients
with inoperable thyroid carcinoma or with local
recurrence, or with remote metastases
concentrating radioiodine in quantities non
sufficient for radical treatment.
Contraindications for radioiodine C31 I)
treatment
D Pregnancy
D Breast-feeding
The contraception for women is necessary
during 12 months after radioiodine treatment.
For men the 4 - 6 months contraception is
recommended.
Method of radioiodine C31 I) administration
D Patient serum TSH concentration should be
above 30 ulU/mi
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